Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
2026 · 2nd Quarter (Apr 1 - June 30)
VERTEX PHARMACEUTICALS INCORPORATED
Filed by STANTON PARK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- STANTON PARK GROUP
- Filing UUID
- 5d1bc0f4-7a87-48c0-a9b0-fc3ac8418ff1
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.